Leuprolide, a peptide-based GnRH receptor superagonist approved for palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty, receives a high association score for premenopausal hormone receptor-positive (HR+) breast cancer. Here, GNRHR is linked to central precocious puberty.